Benjamin C. Smeal - 18 Oct 2024 Form 4 Insider Report for Evoke Pharma Inc (EVOK)

Role
Director
Signature
/s/ Matthew J. D'Onofrio, Attorney-in-fact for Benjamin C. Smeal
Issuer symbol
EVOK
Transactions as of
18 Oct 2024
Net transactions value
$0
Form type
4
Filing time
22 Oct 2024, 17:09:17 UTC
Next filing
22 May 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EVOK Stock Option (Right to Buy) Award $0 +5,833 $0.000000 5,833 18 Oct 2024 Common Stock 5,833 $5.51 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 1/3rd of the total number of shares of common stock subject to the option shall vest following each one-year period after October 18, 2024, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date, so that the option shall be fully vested on the third anniversary of the date of grant.